Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 for Fibrosis in Systemic Sclerosis
NCT00613171Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of imatinib in systemic sclerosis (SSc), sponsored by Novartis. Primary endpoints: Modified Rodnan Skin Score at 48 weeks and Adverse Events and Serious Adverse Events. Started Jan 2008; status: completed.
02
Drugs
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00613171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00613171.